Jade Biosciences, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $55.8 million for the three months ended June 30, 2026, compared to a loss of $32.1 million for the same period in 2025. For the six months ended June 30, 2026, the net loss was $96.1 million, up from $70.3 million in the prior year. Total operating expenses for the second quarter reached $58.9 million, a substantial increase from $27.8 million in the previous year, driven primarily by heightened research and development costs.

The company’s cash and cash equivalents increased to $107.3 million as of June 30, 2026, up from $88.4 million at the end of 2025. Investments also rose significantly to $354.0 million from $247.7 million, reflecting a strategic focus on bolstering its financial position. Jade's total assets amounted to $472.1 million, compared to $349.8 million at the end of 2025. The increase in assets is attributed to successful equity financing efforts, including a public offering that generated approximately $172.5 million in gross proceeds.

Operationally, Jade Biosciences is advancing its clinical pipeline, which includes three product candidates: JADE101, JADE201, and JADE301. The company initiated a Phase 2 clinical trial for JADE101 in May 2026, targeting IgA nephropathy, and reported positive interim data from its Phase 1 trial. JADE201, aimed at treating rheumatoid arthritis, also commenced its Phase 1 trial in May 2026. The company anticipates further clinical data releases in 2027, which will inform its development strategy.

Jade's workforce has expanded, with an increase in employee headcount to support its growing research and development activities. The company expects its operating expenses to continue rising as it progresses through clinical trials and prepares for potential commercialization of its product candidates. Despite the current losses, Jade maintains that its existing cash and investments are sufficient to fund operations for at least the next twelve months, as it continues to seek additional funding through equity offerings and collaborations.

About Jade Biosciences, Inc.

Aerovate Therapeutics, Inc. is a biopharmaceutical company focused on developing inhaled therapies for pulmonary arterial hypertension (PAH), a rare and serious lung disease. Its primary product candidate was AV-101, a dry powder inhaled formulation of imatinib designed to target abnormal cellular proliferation in pulmonary arteries. The company’s business model centers on drug development, clinical trials, and regulatory approval processes targeting PAH patients in the U.S. and Europe.

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov